vs
Side-by-side financial comparison of Monolithic Power Systems (MPWR) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $804.2M, roughly 1.8× Monolithic Power Systems). Monolithic Power Systems runs the higher net margin — 24.0% vs 10.0%, a 14.0% gap on every dollar of revenue. On growth, Monolithic Power Systems posted the faster year-over-year revenue change (26.1% vs -3.5%). Over the past eight quarters, Monolithic Power Systems's revenue compounded faster (25.9% CAGR vs -4.7%).
Monolithic Power Systems, Inc. is an American, publicly traded company headquartered in Kirkland, Washington. It operates in more than 15 locations worldwide.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
MPWR vs OGN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $804.2M | $1.5B |
| Net Profit | $193.2M | $146.0M |
| Gross Margin | 55.3% | 53.6% |
| Operating Margin | 30.0% | — |
| Net Margin | 24.0% | 10.0% |
| Revenue YoY | 26.1% | -3.5% |
| Net Profit YoY | 43.1% | 67.8% |
| EPS (diluted) | $3.92 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $804.2M | $1.5B | ||
| Q4 25 | $751.2M | $1.5B | ||
| Q3 25 | $737.2M | $1.6B | ||
| Q2 25 | $664.6M | $1.6B | ||
| Q1 25 | $637.6M | $1.5B | ||
| Q4 24 | $621.7M | $1.6B | ||
| Q3 24 | $620.1M | $1.6B | ||
| Q2 24 | $507.4M | $1.6B |
| Q1 26 | $193.2M | $146.0M | ||
| Q4 25 | $171.7M | $-205.0M | ||
| Q3 25 | $179.8M | $160.0M | ||
| Q2 25 | $135.0M | $145.0M | ||
| Q1 25 | $135.1M | $87.0M | ||
| Q4 24 | $1.3B | $109.0M | ||
| Q3 24 | $144.4M | $359.0M | ||
| Q2 24 | $100.4M | $195.0M |
| Q1 26 | 55.3% | 53.6% | ||
| Q4 25 | 55.2% | 49.2% | ||
| Q3 25 | 55.1% | 53.5% | ||
| Q2 25 | 55.1% | 54.8% | ||
| Q1 25 | 55.4% | 55.6% | ||
| Q4 24 | 55.4% | 56.3% | ||
| Q3 24 | 55.4% | 58.3% | ||
| Q2 24 | 55.3% | 58.4% |
| Q1 26 | 30.0% | — | ||
| Q4 25 | 26.6% | -9.8% | ||
| Q3 25 | 26.5% | 15.2% | ||
| Q2 25 | 24.8% | 14.4% | ||
| Q1 25 | 26.5% | 6.7% | ||
| Q4 24 | 26.3% | 8.1% | ||
| Q3 24 | 26.5% | 13.1% | ||
| Q2 24 | 23.0% | 14.6% |
| Q1 26 | 24.0% | 10.0% | ||
| Q4 25 | 22.9% | -13.6% | ||
| Q3 25 | 24.4% | 10.0% | ||
| Q2 25 | 20.3% | 9.1% | ||
| Q1 25 | 21.2% | 5.8% | ||
| Q4 24 | 201.8% | 6.8% | ||
| Q3 24 | 23.3% | 22.7% | ||
| Q2 24 | 19.8% | 12.1% |
| Q1 26 | $3.92 | $0.55 | ||
| Q4 25 | $3.50 | $-0.78 | ||
| Q3 25 | $3.74 | $0.61 | ||
| Q2 25 | $2.81 | $0.56 | ||
| Q1 25 | $2.81 | $0.33 | ||
| Q4 24 | $25.71 | $0.42 | ||
| Q3 24 | $2.95 | $1.38 | ||
| Q2 24 | $2.05 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7B | — |
| Total Assets | $4.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $574.0M | ||
| Q3 25 | $1.3B | $672.0M | ||
| Q2 25 | $1.1B | $599.0M | ||
| Q1 25 | $1.0B | $547.0M | ||
| Q4 24 | $862.9M | $675.0M | ||
| Q3 24 | $1.5B | $763.0M | ||
| Q2 24 | $1.3B | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.5B | $752.0M | ||
| Q3 25 | $3.4B | $906.0M | ||
| Q2 25 | $3.2B | $733.0M | ||
| Q1 25 | $3.1B | $542.0M | ||
| Q4 24 | $3.0B | $472.0M | ||
| Q3 24 | $2.4B | $493.0M | ||
| Q2 24 | $2.2B | $144.0M |
| Q1 26 | $4.4B | — | ||
| Q4 25 | $4.2B | $12.9B | ||
| Q3 25 | $4.1B | $13.6B | ||
| Q2 25 | $3.9B | $13.5B | ||
| Q1 25 | $3.7B | $13.2B | ||
| Q4 24 | $3.5B | $13.1B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.6B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPWR
Segment breakdown not available.
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
